Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.
Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Weight-Loss Drugs Cut Drug and Alcohol Abuse, According to New Study
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.
UK plans weight loss drug trials to get people back to work
The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over a quarter of UK adults suffered from obesity in 2023 according to government data.
This is Huge News For Eli Lilly Investors
As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
STAT10d
Eli Lilly, Insitro ink a new kind of AI drug development deal
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the ...
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...
Pharmaceutical Technology9d
Lilly and insitro team up to develop AI-powered siRNA metabolic drugs
Eli Lilly and insitro’s deal focuses on advancing potential new medicines for metabolic diseases based on ... platform ...
GlobalData on MSN2d
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use AI and tech to transform the company.